By Center for Breakthrough Medicine – BIOPHARMADIVE
The enormous impact the pandemic had on the biopharma industry is unmistakable, as evidenced by the unprecedented investments that took place in the cell and gene therapy (CGT) space.
In January 2022, the Milken Institute published a report, “Cell and Gene Therapies: Looking Ahead to 2022,”1 describing the growth of the CGT industry in 2021. In the U.S., 7 new therapies were approved for commercialization, a similar number were approved in Europe, and greater than 1,000 therapies were in development, with 75 expected to be approved in the U.S. by 2030.
